#United States #San Diego #AACR 2026 #Kalohexis #Paradox Trial

Kalohexis Unveils Trial Updates at AACR 2026

Kalohexis, a prominent clinical-stage biotechnology firm that is revolutionizing the approach to metabolic diseases, has announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026. This significant event will take place from April 17-22, 2026, in sunny San Diego, California. The company is set to present crucial findings that could advance the treatment of cachexia, particularly in patients dealing with advanced colorectal cancer.

Overview of Kalohexis

Founded on the promise of leveraging the melanocortin system, Kalohexis aims to transform how metabolic diseases are treated by focusing on the body’s innate metabolic regulatory systems. Their research particularly targets conditions like obesity and cancer cachexia, offering new hope through the development of cutting-edge therapeutic peptides.

At the AACR 2026 meeting, Kalohexis will feature a poster titled 'A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy: The Paradox Trial.' This trial is particularly groundbreaking as it explores the effectiveness of mifomelatide, a dual MC3R/MC4R antagonist, in combating cachexia—a debilitating condition characterized by weight loss and muscle wasting commonly associated with cancer.

Key Presentation Details

The key presentation will occur on April 21, 2026, between 9:00 AM and 12:00 PM PT in Poster Section 51, Board #14. During this session, Endevica Bio, in collaboration with Kalohexis, will present critical insights regarding the ongoing Phase 2 Paradox trial that commenced in Q2 2025. The trial’s primary focus includes evaluating the safety, tolerability, and efficacy of the investigational drug, mifomelatide.

Trial Objectives and Endpoints

The Paradox trial is designed to assess several primary and secondary endpoints:

• - Primary Endpoints:

- Change in body weight from baseline
- Incidence and severity of adverse events (AEs)
- Incidence of laboratory or vital sign abnormalities

• - Secondary Endpoints:

- Change in appetite from baseline
- Quality of life improvements

With the increasing prevalence of metabolic disorders and the burden of cancer cachexia, this research holds significant promise for enhancing patient care standards and improving overall treatment outcomes.

The Future of Kalohexis

As Kalohexis continues to lead the charge in the biotechnology sector, they are well positioned to innovate treatment options that address some of the most challenging aspects of metabolic diseases. Their dedication to researching and developing new therapeutic avenues underscores their commitment to significantly improving the lives of patients affected by these debilitating conditions.

To learn more about Kalohexis and their groundbreaking research initiatives, visit their official website or follow them on social media platforms like LinkedIn and X. This AACR 2026 meeting may just mark the beginning of a new chapter in metabolic disease management and cancer care!

Contact Details

For media inquiries or more information, contact Argot Partners at [email protected]

Conclusion

The upcoming AACR 2026 presentation by Kalohexis not only highlights their innovative research but also reinforces their role in the fight against metabolic diseases. As the health community gathers in San Diego, the insights shared may pave the way for future advancements and expectations in cancer care and beyond.